Last update Feb. 12, 2020

Dornase Alfa

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

A synthetic deoxyribonuclease obtained by human recombinant technology (rhDNase). A protein structure formed by 260 amino acids. It behaves like an enzyme that hydrolyzes DNA in mucus. Indicated as a mucolytic in patients with cystic fibrosis.
Administration via inhalation once to twice a day.

Since the last update we have not found published data on its excretion in breastmilk.

Systemic absorption is very low and there is no accumulation. DNase is normally present in human serum. Endogenous plasma levels of DNase were not significantly modified after inhalation treatment over several months (FDA 2018, AEMPS 2015).

Its very high molecular weight makes it very unlikely it will transfer into breastmilk in significant amounts (AEMPS 2015).

Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically zero oral bioavailability), which hinders transfer to infant plasma from breastmilk.


We do not have alternatives for Dornase Alfa since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dornase Alfa is also known as

Dornase Alfa in other languages or writings:


Dornase Alfa belongs to these groups or families:


Main tradenames from several countries containing Dornase Alfa in its composition:


Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 29.250 daltons
3 - 4 hours


  1. FDA - Genentech. Dornase Alfa (Pulmozyme). Drug Summary. 2018 Full text (in our servers)
  2. AEMPS - Roche. Dornasa Alfa (Pulmozyme). Ficha técnica. 2015 Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM